2026 Q1 -tulosraportti
Vain PDF
5 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 461 | - | - | ||
| 9 | - | - | ||
| 9 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6.5.Fantastic reporting today - and the market took it well.
·3 päivää sitten · MuokattuIt is clear that the approval will drive the stock price high up, but I actually think that the risk of acquisition is much greater.. establishing a sales organization costs a fortune, so either a licensing deal or a "real partner collaboration" is preferable... they only have one product on the shelf- ·25.2.This is an incomprehensibly overlooked winner stock.. ***DISCLAMER - I own it Infant Bacterial Therapeutics (IBT) is, in nin optics, on the verge of a historic FDA approval of IBP-9414 against NEC in premature infants – and it is the mortality reduction that makes it a no-brainer! Life-saving data speaks for itself The Phase 3 study showed a clear 27% ( 45%) lower mortality with IBP-9414 compared to placebo, in a condition where NEC affects with 10-50% infant mortality. FDA has already granted Breakthrough Therapy Designation precisely for this massive potential to save lives – prioritized review and close dialogue are in place, and BLA submission is coming soon in 2026. Highly probable success With orphan drug status, positive data and the unmet need to stop intestinal necrosis in the weakest infants, FDA approval is as good as secured. Mortality alone massively tips the scales – IBT is on its way to revolutionize neonatal care HOW CAN FDA reject ... just the fact that one can so extremely avoid deaths is proof in itself... *** Remember my DISCLAMER·27.2. · MuokattuCompletely agree - also have quite a few of them by now. And if they get an approval, there are also good chances for a voucher that can be sold for more than the entire company is worth today (USD 100-200mill = 1-2 billion SEK). If we take today's value 710 + 1.3 (USD 150 for vouche) = 2 billion. Previous peak is price 275 = 3.6 billion - i.e. an approval only needs to be valued at 1.6 billion for us to see 275 on the horizon. I think it will probably take some time to get there - but I wonder if we won't have to test it at some point!?
- ·9.2. · MuokattuWhat do you think will happen if they get a voucher for a potential sales value of USD 150-200 mill with a marketcap currently just under SEK 700 🌞🌞 That's a 3-4x increase in market value as cash PLUS an approved product !??!!
·12.2.Completely agree, it can still go both ways. As I also wrote, a lot depends on the validation of their production. And it wouldn't be the first (or last) biotech company to stumble just before the finish line. So no, a lot can still happen. But exciting to follow. - ·26.11.2025Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣
·26.11.2025Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do! - ·20.11.2025Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.5.Fantastic reporting today - and the market took it well.·3 päivää sitten · MuokattuIt is clear that the approval will drive the stock price high up, but I actually think that the risk of acquisition is much greater.. establishing a sales organization costs a fortune, so either a licensing deal or a "real partner collaboration" is preferable... they only have one product on the shelf
- ·25.2.This is an incomprehensibly overlooked winner stock.. ***DISCLAMER - I own it Infant Bacterial Therapeutics (IBT) is, in nin optics, on the verge of a historic FDA approval of IBP-9414 against NEC in premature infants – and it is the mortality reduction that makes it a no-brainer! Life-saving data speaks for itself The Phase 3 study showed a clear 27% ( 45%) lower mortality with IBP-9414 compared to placebo, in a condition where NEC affects with 10-50% infant mortality. FDA has already granted Breakthrough Therapy Designation precisely for this massive potential to save lives – prioritized review and close dialogue are in place, and BLA submission is coming soon in 2026. Highly probable success With orphan drug status, positive data and the unmet need to stop intestinal necrosis in the weakest infants, FDA approval is as good as secured. Mortality alone massively tips the scales – IBT is on its way to revolutionize neonatal care HOW CAN FDA reject ... just the fact that one can so extremely avoid deaths is proof in itself... *** Remember my DISCLAMER·27.2. · MuokattuCompletely agree - also have quite a few of them by now. And if they get an approval, there are also good chances for a voucher that can be sold for more than the entire company is worth today (USD 100-200mill = 1-2 billion SEK). If we take today's value 710 + 1.3 (USD 150 for vouche) = 2 billion. Previous peak is price 275 = 3.6 billion - i.e. an approval only needs to be valued at 1.6 billion for us to see 275 on the horizon. I think it will probably take some time to get there - but I wonder if we won't have to test it at some point!?
- ·9.2. · MuokattuWhat do you think will happen if they get a voucher for a potential sales value of USD 150-200 mill with a marketcap currently just under SEK 700 🌞🌞 That's a 3-4x increase in market value as cash PLUS an approved product !??!!·12.2.Completely agree, it can still go both ways. As I also wrote, a lot depends on the validation of their production. And it wouldn't be the first (or last) biotech company to stumble just before the finish line. So no, a lot can still happen. But exciting to follow.
- ·26.11.2025Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣·26.11.2025Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do!
- ·20.11.2025Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 461 | - | - | ||
| 9 | - | - | ||
| 9 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.5.Fantastic reporting today - and the market took it well.·3 päivää sitten · MuokattuIt is clear that the approval will drive the stock price high up, but I actually think that the risk of acquisition is much greater.. establishing a sales organization costs a fortune, so either a licensing deal or a "real partner collaboration" is preferable... they only have one product on the shelf
- ·25.2.This is an incomprehensibly overlooked winner stock.. ***DISCLAMER - I own it Infant Bacterial Therapeutics (IBT) is, in nin optics, on the verge of a historic FDA approval of IBP-9414 against NEC in premature infants – and it is the mortality reduction that makes it a no-brainer! Life-saving data speaks for itself The Phase 3 study showed a clear 27% ( 45%) lower mortality with IBP-9414 compared to placebo, in a condition where NEC affects with 10-50% infant mortality. FDA has already granted Breakthrough Therapy Designation precisely for this massive potential to save lives – prioritized review and close dialogue are in place, and BLA submission is coming soon in 2026. Highly probable success With orphan drug status, positive data and the unmet need to stop intestinal necrosis in the weakest infants, FDA approval is as good as secured. Mortality alone massively tips the scales – IBT is on its way to revolutionize neonatal care HOW CAN FDA reject ... just the fact that one can so extremely avoid deaths is proof in itself... *** Remember my DISCLAMER·27.2. · MuokattuCompletely agree - also have quite a few of them by now. And if they get an approval, there are also good chances for a voucher that can be sold for more than the entire company is worth today (USD 100-200mill = 1-2 billion SEK). If we take today's value 710 + 1.3 (USD 150 for vouche) = 2 billion. Previous peak is price 275 = 3.6 billion - i.e. an approval only needs to be valued at 1.6 billion for us to see 275 on the horizon. I think it will probably take some time to get there - but I wonder if we won't have to test it at some point!?
- ·9.2. · MuokattuWhat do you think will happen if they get a voucher for a potential sales value of USD 150-200 mill with a marketcap currently just under SEK 700 🌞🌞 That's a 3-4x increase in market value as cash PLUS an approved product !??!!·12.2.Completely agree, it can still go both ways. As I also wrote, a lot depends on the validation of their production. And it wouldn't be the first (or last) biotech company to stumble just before the finish line. So no, a lot can still happen. But exciting to follow.
- ·26.11.2025Ok - not very clever investors we're dealing with here. I'm surprised that after an FDA meeting they are pursuing the fast accelerated process instead of the longer standard BLA.!! 🤣·26.11.2025Yes, but maybe they want to get the product out faster!? Now that they have a manufacturer in Recipharm!? Sometimes we don't have the full picture! My impression is that they have very good knowledge of both patents and studies, considering BioGaia! We'll see! Prematurely born children are being born and saved more and more nowadays….. important what they do!
- ·20.11.2025Another high-potential possibility is that we are acquired. Bio companies in niche areas rarely succeed alone due to a simple reason: they lack the competence to market the product, even though Infant B. "only" needs to enter absolute special hospitals, so a market-leading Pharma will presumably take over the marketing rights per region, USA. Europe. Asia will certainly be taken over by a Japanese company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 461 | - | - | ||
| 9 | - | - | ||
| 9 | - | - | ||
| 1 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 636 | 3 636 | 0 | 0 |